HIV Infections Clinical Trial
To establish the incidence, clinical spectrum, and natural history of cardiac dysautonomia as defined by heart rate spectral analysis in both HIV infected and noninfected children and to evaluate the value of heart rate spectral analysis for predicting dysrhythmias and sudden death in infants and children born to HIV infected mothers.
BACKGROUND:
The magnitude of clinical problems associated with autonomic dysfunction in children with
symptomatic HIV infection is great. Hemodynamic abnormalities, dysrhythmias, unexplained
arrest and/or sudden death are common in HIV positive children, especially when acute
deterioration, interventions or neurologic involvement is present. If cardiac dysautonomia
is predictive of adverse outcomes in HIV infected children, then a future prospective trial
of beta-adrenergic antagonist therapy may be warranted.
DESIGN NARRATIVE:
An analysis was performed on data collected under the NHLBI-sponsored multicenter study
entitled 'Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted
Human Immunodeficiency Virus (HIV) Infection' and abbreviated P2C2. The P2C2 study was
performed in a prospectively defined cohort of 150 children with HIV infection and 350
uninfected control children born to HIV infected women who had been followed since the first
month of life to provide understanding of cardiac dysautonomia in early HIV infection. In
addition, 198 children with symptomatic HIV infection were analyzed to provide an assessment
of cardiac dysautonomia in later stages of pediatric HIV infection. Heart rate spectral
analyses were performed on 2196 Holter monitor recordings from these patients followed at
the five P2C2 clinical centers to capture noninvasively the time varying contributions of
the sympathetic and parasympathetic nervous system to the control of heart rate throughout
the course of a day. The spectral balance parameters and the changing response of heart rate
to the electrocardiogram-derived respiratory signal characterized the responsiveness of the
sympathetic and parasympathetic nervous system at rest and during the events of a normal
day. Autonomic function data were electronically transmitted to the P2C2 data coordinating
center at the Cleveland Clinic and analyzed along with other P2C2 data (eg. infectious,
immunologic, growth, renal, neuroendocrine, pulmonary and cardiac) to determine their risk
factor potential for cardiac dysautonomia.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |